This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Rosiglitazone on ADMA in Critical Illness

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2006 by VU University Medical Center.
Recruitment status was:  Recruiting
Information provided by:
VU University Medical Center Identifier:
First received: December 7, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
The purpose of this study is to determine whether Rosiglitazone,decreases the ADMA concentration and thereby increases the arginine/ADMA ratio of critically ill patients.

Condition Intervention Phase
Critical Illness Multiple Organ Failure Drug: Rosiglitazone Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by VU University Medical Center:

Primary Outcome Measures:
  • ADMA concentration

Secondary Outcome Measures:
  • SOFA score
  • Organ function
  • Mortality

Estimated Enrollment: 30
Study Start Date: April 2006
Estimated Study Completion Date: December 2007
Detailed Description:
Endothelial vasodilatation dysfunction precedes the development of arteriosclerosis. The endothelium plays a pivotal role in the control of the vascular tone by releasing nitric oxide (NO). The amino acid arginine is the sole substrate for the enzyme NO synthase (NOS). Asymmetric dimethylarginine (ADMA) is an endogenous derivative of arginine that inhibits NOS. Thus the arginine/ADMA ratio an important determinant of NO production by NOS. ADMA is an independent risk factor for cardiovascular disease, but elevated levels of ADMA have also been shown to be a strong independent predictor of ICU mortality. The central mechanism by which ADMA may cause deterioration in critically ill patients is by impairing organ blood flow and reducing cardiac function, especially during stress. Accumulation of ADMA could thereby be a causative factor in the development multi organ failure (MOF). Thus inhibition of NO production by ADMA may become especially important when cardiac demand is increased.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • critically ill patients
  • age between 18 and 75 years
  • SOFA score > 7

Exclusion Criteria:

  • history of Diabetes mellitus
  • history of hypercholesterolemia
  • history of hyperhomocysteinemia
  • impaired hepatic function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00409097

Contact: Milan C Richir, MD 0031 20 4443601

VU University Medical Center Recruiting
Amsterdam, Netherlands, 1081 HV
Contact: Milan C Richir, MD    0031 20 4443601   
Principal Investigator: Milan C Richir, MD         
Sponsors and Collaborators
VU University Medical Center
Study Director: Paul am Leeuwen van, MD, PhD VU University Medical Center
  More Information Identifier: NCT00409097     History of Changes
Other Study ID Numbers: HK0506
Study First Received: December 7, 2006
Last Updated: December 7, 2006

Keywords provided by VU University Medical Center:
Critical illness

Additional relevant MeSH terms:
Critical Illness
Multiple Organ Failure
Disease Attributes
Pathologic Processes
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on July 21, 2017